Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Core Insights - Sunshine Biopharma Inc. has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity against SARS Coronavirus (SARS-CoV-2) [1] - The research was conducted in collaboration with the University of Arizona [1] Company Developments - The new protease inhibitors are aimed at providing life-saving medicines in therapeutic areas including oncology and antivirals [1] - The ongoing collaboration with the University of Arizona highlights the company's commitment to advancing its research capabilities [1]